Leerink Partnrs Has Negative Forecast for MAZE Q1 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Leerink Partnrs decreased their Q1 2025 EPS estimates for shares of Maze Therapeutics in a research note issued to investors on Monday, March 31st. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.64) for the quarter, down from their previous estimate of ($0.58). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Maze Therapeutics’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.33) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($2.55) EPS.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Monday, March 31st. The company reported ($18.32) earnings per share for the quarter, missing the consensus estimate of ($7.60) by ($10.72).

MAZE has been the subject of several other research reports. JPMorgan Chase & Co. initiated coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They set an “overweight” rating and a $30.00 target price for the company. Leerink Partners began coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an “outperform” rating and a $28.00 price objective for the company. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 25th. Finally, Guggenheim reiterated a “buy” rating and set a $19.00 price target on shares of Maze Therapeutics in a report on Wednesday. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Stock Performance

Shares of MAZE stock opened at $9.07 on Thursday. Maze Therapeutics has a twelve month low of $8.33 and a twelve month high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.